|
Category:stabilizing agents
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | white fine crystalline solid (est) |
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 137.50 °C. @ 760.00 mm Hg
|
| Boiling Point: | 355.10 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 335.00 °F. TCC ( 168.50 °C. ) (est)
|
| logP (o/w): | 1.580 |
| Soluble in: |
| | water, 766 mg/L @ 25 °C (exp) | | | water, 2485 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-dog LDLo 260 mg/kg
National Technical Information Service. Vol. PB282-666
oral-guinea pig LD50 1870 mg/kg
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Toxicology and Applied Pharmacology. Vol. 2, Pg. 23, 1960.
oral-hamster LD50 1690 mg/kg
BEHAVIORAL: COMA
BEHAVIORAL: ATAXIA
CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP
Pharmazie. Vol. 8, Pg. 572, 1953.
unreported-man LDLo 74 mg/kg
"Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970.
intraperitoneal-mouse LD50 540 mg/kg
Yakugaku Zasshi. Journal of Pharmacy. Vol. 81, Pg. 659, 1961.
oral-mouse LD50 866 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 28, Pg. 1644, 1978.
oral-rabbit LD50 2500 mg/kg
Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. Vol. 21(9), Pg. 53, 1977.
intraperitoneal-rat LD50 634 mg/kg
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 62, Pg. 11, 1966.
oral-rat LD50 1650 mg/kg
CARDIAC: PULSE RATE
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Toxicology and Applied Pharmacology. Vol. 1, Pg. 240, 1959.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 1625 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 25, 1958.
subcutaneous-rabbit LD50 1000 mg/kg
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 719, 1971.
|
| Inhalation Toxicity: |
inhalation-mouse LC50 33900 mg/m3
Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 34(10), Pg. 36, 1969.
|
Safety in Use Information:
| Category: | | stabilizing agents |
| Recommendation for phenacetin usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for phenacetin flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
| (IUPAC): | Atomic Weights of the Elements 2011 (pdf) |
| Videos: | The Periodic Table of Videos |
| tgsc: | Atomic Weights use for this web site |
| (IUPAC): | Periodic Table of the Elements |
| CHEBI: | View |
| CHEMBL: | View |
| KEGG (GenomeNet): | C07591 |
| HMDB (The Human Metabolome Database): | Search |
| Export Tariff Code: | 2924.29.7690 |
| ChemSpider: | View |
| Wikipedia: | View |
Formulations/Preparations:
•grades: technical; usp, as phenacetin.
•apcabuff contains 2.5 g phenacetin per tablet.
•pharmex flu capsules contain 2.5 g phenacetin per tablet.
•phencaset contains 150 mg phenacetin per tablet.
•pyradyne contains 150 mg phenacetin per tablet.
•it is available in 300 mg doses as tablets containing 94-106% of the stated amount of phenacetin and is also available in the usa as tablets containing 150 mg phenacetin in combination with 230 mg aspirin and 15 or 30 mg caffeine, or with 230 mg aspirin, 30 mg caffeine, and 8, 15, or 60 mg codeine phosphate and containing 90-110% of the stated amount of phenacetin. former in usa
|
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | acetamide, N-(4-ethoxyphenol)- | | | acetamide, N-(4-ethoxyphenyl)- | | | acetamide, N-(4-ethoxyphenyl)- (9CI) | | 1- | acetamido-4-ethoxybenzene | | | acetanilide, 4'-ethoxy- | | | acetanilide, p-ethoxy- | | | aceto-4-phenetidine | | | aceto-p-phenetidin | | | aceto-para-phenalide | | | aceto-para-phenetidide | | 4- | acetophenetidide | | p- | acetophenetidide | | para- | acetophenetidide | | | acetophenetidin | | | acetophenetidine | | para- | acetophenetidine | | | acetophenetin | | | acetphenetidin | | para- | acetphenetidin | | N- | acetyl-4-ethoxyaniline | | N- | acetyl-p-ethoxyaniline | | 1- | acetyl-p-phenetidin | | N- | acetyl-p-phenetidine | | N- | acetyl-para-phenetidine | | 4-( | acetylamino)phenetole | | | achrocidin | | | clistanol | | | codempiral | | | commotional | | | contradouleur | | | coryban-D | | | daprisal | | | dasikon | | | dolostop | | | dolviran | | | empiral | | | emprazil | | 4- | ethoxyacetanilide | | 4'- | ethoxyacetanilide | | p- | ethoxyacetanilide | | para- | ethoxyacetanilide | | N-(4- | ethoxyphenol)acetamide | | N-(4- | ethoxyphenyl)-acetamide | | N-(4- | ethoxyphenyl)acetamide | | N-[4-( | ethyloxy)phenyl]acetamide | | | fenidina | | | fortacyl | | | helvagit | | | melaforte | | p- | phenacetin | | para- | phenacetin | | | phenacetine | | | phenacetinum | | | phenacitin | | | phenacon | | p- | phenetidine, N-acetyl- | | | phenodyne | | | quadronal | | | stellacyl | | | terracydin | | | veganine | | | wigraine |
Articles:
| PubMed:Highly sensitive LC-MS/MS method for determination of galantamine in rat plasma: application to pharmacokinetic studies in rats. |
| PubMed:Simultaneous determination of Guanfu base G and its active metabolites by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study. |
| PubMed:A simple assay for the simultaneous determination of human plasma albendazole and albendazole sulfoxide levels by high performance liquid chromatography in tandem mass spectrometry with solid-phase extraction. |
| PubMed:Development and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study. |
| PubMed:Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes. |
| PubMed:Increased exposure of vitamin A by Chrysanthemum morifolium Ramat extract in rat was not via induction of CYP1A1, CYP1A2, and CYP2B1. |
| PubMed:Effects of Ougan juice on P450 activities using a cocktail method. |
| PubMed:Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. |
| PubMed:Technical modification of the Balb/c 3T3 cell transformation assay: the use of serum-reduced medium to optimise the practicability of the protocol. |
| PubMed:The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes. |
| PubMed:Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol. |
| PubMed:[Novel potential uses of thalidomide in the management of pain? A review of the literature]. |
| PubMed:Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. |
| PubMed:Neonatal mouse model: review of methods and results. |
| PubMed:Epidemiology and etiology of premalignant and malignant urothelial changes. |
| PubMed:Dose selection for carcinogenicity studies of pharmaceuticals: systemic exposure to phenacetin at carcinogenic dosage in the rat. |
| PubMed:Optimum conditions for the 13C-phenylalanine breath test. |
| PubMed:Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials. |
| PubMed:A rapid, specific, and sensitive method for the determination of acetylation phenotype using dapsone. |
| PubMed:Influence of diet and nutritional status on drug metabolism. |
| PubMed:Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) by human liver microsomes. |
| PubMed:Nitrosamine formation via non-prescription drugs? |
| PubMed:Metabolic activation and nucleic acid binding of acetaminophen and related arylamine substrates by the respiratory burst of human granulocytes. |
| PubMed:Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. |
| PubMed:The effect of food dye and other environmental substances on the host defense reaction in mice in relation to virus infection. |
| PubMed:Food-borne amines and amides as potential precursors of endogenous carcinogens. |
| PubMed:Drugs, food additives and natural products as promoters in rat urinary bladder carcinogenesis. |
| PubMed:Food interactions affecting the absorption of analgesic and anti-inflammatory agents. |
| PubMed:Proposal to remove phenacetin from analgesics. |
| PubMed:Tobacco use, occupation, coffee, various nutrients, and bladder cancer. |
| PubMed:Research review. Interactions between environmental chemicals and drug biotransformation in man. |
| PubMed:Influence of food on the bioavailability of drugs. |
| PubMed:Discriminative stimulus properties of analgesic drugs: narcotic versus non-narcotic analgesics. |
| PubMed:Urinary enzymes and kidney damage by aspirin and phenacetin. |
| PubMed:Inhibitory effects of lipophilic acids and related compounds on bacteria and mammalian cells. |
| PubMed:Caffeine in America's food and drug habits. |
| PubMed:Unravelling analgesic nephropathy. |
| PubMed:General and renal toxicity of phenacetin, paracetamol and some anti-mitotic agents in the rat. |
| PubMed:Phenacetin as a carcinogen: an unsatisfactory picture. |
| PubMed:Drug safety: experimental programs. |
|
a phenylacetamide that was formerly used in analgesics but nephropathy and methemoglobinemia led to its withdrawal from the market. (from smith and reynard, textbook of pharmacology,1991, p431)
|
3D/inchi